Opposite effects of bone marrow-derived cells transplantation in MPTP-rat model of Parkinson's disease: A comparison study of mononuclear and mesenchymal stem cells

International Journal of Medical Sciences

Volumn 11, Issue 10, 2014, Pages 1049-1064

  Capitelli, Caroline Santos ^a   Lopes, Carolina Salomão ^b   Alves, Angélica Cristina ^b   Barbiero, Janaína ^a   Oliveira, Lucas Felipe ^b   da Silva, Valdo José Dias ^b   Vital, Maria Aparecida Barbato Frazão ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Federal University of Triângulo Mineiro   (Brazil)

Author keywords

Bone marrow mononuclear cells; Cell therapy; Mesenchymal stem cells; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIGEN; CD45 ANTIGEN; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1 ANTIGEN; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; BRAIN TISSUE; CELL ACTIVATION; CELL FUNCTION; CELL STRUCTURE; CELL TRACKING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FORCED SWIM TEST; IMMOBILITY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MESENCHYMAL STEM CELL; MICROGLIA; MONONUCLEAR CELL; MORPHOLOGICAL TRAIT; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NERVE CELL LESION; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; RAT; SHAM PROCEDURE; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; BONE MARROW CELL; CYTOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; BONE MARROW CELLS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; MALE; MESENCHYMAL STROMAL CELLS; PARKINSON DISEASE; RATS; RATS, WISTAR; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 84905513573     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8182     Document Type: Article

References (64)

1. Dauer W, Przedborski S. Parkinson's disease: mechanism and models. Neuron. 2003;39:889-909.
2. Chaudhurt KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464-474.
3. Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in PD. J Neurol Sci. 2010;289:81-88.
4. Ferrer I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol. 2009;88:89-103.
5. Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res. 2001;124:9-18.
6. Capitelli C, Sereniki A, Lima MM, Reksidler AB, Tufik S, Vital MABF. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol. 2008;594:101-108.
7. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trend Pharmacol Sci. 2003;24:395-401.
8. Takahashi H, Wakabayashi K. Controversy: Is Parkinson's disease entity? Yes. Parkinsonism Relat Disord. 2005;11:S31-S37.
9. Schulz JB, Falkenburger BH. Neuronal pathology in Parkinson's disease. Cell Tissue Res. 2004;318:135-147.
10. Chao YX, He BP, Tay SS. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. J Neuroimmunol. 2009;216:39-50.
11. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975;195:453-464.
12. Poewe W, Mahlknecht P. The Clinical progression of PD. Parkinsonism Relat Disord. 2009;15:S28-32.
13. Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O. Dopamine release from nigral transplants visualized in vivo a Parkinson's patient. Nat Neurosci. 1999;2:1137-1140.
14. Lu D, Mahmood A, Wang L, Li Y, Lu M, Chopp M. Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outocome. Neuroreport. 2001; 12:559-63.
15. Giraldi-Guimarães A, Rezende-Lima M, Bruno FP, Mendez-Otero R. Treatment with bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats. Brain Res. 2009;1266:108-120.
16. Shintani A, Nakao N, Kakishita K, Itakura T. Protection of dopamine neurons by bone marrow stromal cells. Brain Res. 2007;1186:48-55.
17. Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Act. 2009;1792:688-702.
18. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247:574-7.
19. Kim JH, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sánchez-Pernaute R, Bankiewicz K, McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418:50-6.
20. Danielyan L, Schäfer R, Von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, Lourhmati A, Klopfer T, Schaumann F, Schmid B, Koehle C, Proksch B, Weissert R, Reichardt HM, van den Brandt J, Buniatian GH, Schwab M, Gleiter CH, Frey WH. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of PD. Rejuvenation Res. 2011;14:1-14.
21. Sayles M, Jain M, Barker RA. The cellular repair of the brain in Parkinson's disease - past, present and future. Transpl Immunol. 2004;12:321-42.
22. Hall VJ, Li JY, Brundin P. Restorative cell therapy for PD: a quest for the perfect cell. Semin Cell Dev Biol. 2007;18:859-869.
23. Orkin SH. Diversification of hematopoietic stem cells to specific lineages. Nat Rev Genet. 2000;1:57-64.
24. Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol. 2001;17:387-403.
25. Singer NG and Caplan AI. Mesenchymal stem cells: Mechanism of inflammation. Annu Rev Pathol Mech Dis. 2011;6:457-78.
26. Strauer BE and Ran KS. Stem cell therapy in perspective. Circulation. 2003; 107:929-934.
27. Shetty P, Ravindran G, Sarang S, Thakur AM, Rao HS, Viswanathan C. Clinical grade mesenchymal stem cells transdifferentiated under xenofree conditions alleviates motor deficiencies in a rat model of Parkinson's disease. Cell Biol Int. 2009;33:830-8.
28. Venkataramana, NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, Dixit A, Rao DK, Das M, Jan M, Gupta PK, Totey SM. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res. 2010;155:62-70.
29. Thomas MG, Stone L, Evill L, Ong S, Ziman M, Livia H. Bone marrow stromal cells as replacement for Parkinson's disease: generation of an anatomical but not functional neuronal phenotype. Transl Res. 2011;157:56-63.
30. Lindvall O, Björklund A. Cell Therapy in Parkinson's disease. NeuroRx. 2004;1:382-93.
31. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic Press. 1986.
32. Neuhuber B, Swanger SA, Howard L, Mackay A, FISCHER I. Effect of platting density and culture time on bone marrow stromal cell characteristic. Exp Hematol. 2008;36:1176-1185.
33. Broadhurst PL. Experiments in psychogenetics. In: Eisenk H.J, Ed. Experiments in personality. London: Routledge and Kegan Paul. 1960: 52-71.
34. Sedelis M, Schwarting RKW, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res. 2001;125:109-125.
35. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol. 1997;8:523-532.
36. Kim Y, Park H, Lee G, Bang O, Ahn Y, Joe E, Kim H, Lee P. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia. 2009;57:13-23.
37. Wirenfeldt M, Clare R, Tung S, Bottini A, Mathern G, Vinters H. Increased activation of Iba1+ microglia in pediatric epilepsy patients with Rasmussen's encephalitis compared with cortical dysplasia and tuberous sclerosis complex. Neurobiol Dis. 2009;34:432-440.
38. Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Abo-Ramadan U, Tatlisumak T. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neurosci. 2008; 153(1):175-81.
39. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science. 1984;224:1451-1453.
40. Collins LM, Toulouse A, Connor TJ, Nolan YM. Contributions of central and systemic inflammation to the pathophysiology of PD. Neuropharmacol. 2012;62:2154-2168.
41. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003;106:518-526.
42. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after MPTP administration. Ann Neurol. 2003;54:599-604.
43. Lima MMS, Reksidler AB, Zanata SM, Machado HB, Tufik S, Vital MABF. Different parkinsonism models produced time-dependent induction COX-2 in the substantia nigra of rats. Brain Res. 2006;1101:117-125.
44. Hathaway CA, Percy WH, Williams JL. Effects of free radicals and leukocytes on increases in blood-brain barrier permeability during colitis. Dig Dis Sci. 2000;45:967-75.
45. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, Jin BK. The role of neuroinflammation on the pathogenesis of PD. BMB Rep. 2010;43:225-232.
46. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson's disease. J Clin Invest. 2009;119:182-192.
47. Kortekaas R, Leenders KL, Van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH. Blood brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann Neurol. 2005;57:176-179.
48. Franco EC, Cardoso MM, Gouvêia A, Pereira A, Gomes-Leal W. Modulation of microglial activation enhances neuroprotection and functional recovery derived from bone marrow mononuclear cell transplantation after cortical ischemia. Neurosci Res. 2012;73:122-132.
49. Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal. 2009;11:2151-2166.
50. McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and diseases of aging. Neurobiol Aging. 2005;26:94-97.
51. Doorn KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, Drukarch B, van Dam AM. Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. Prog in Neurobiol. 2012;98:222-238.
52. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neurosc. 1990;39:151-170.
53. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosc. 2000;20:6309-6316.
54. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Oqusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57:168-75.
55. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of PD. Nat Med. 1999;5:1403-09.
56. McGeer PL, Yasojima K, McGeer EG. Inflammation in PD. Adv Neurol. 2001;86:83-9.
57. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285-91.
58. Cosenza-Nashat MA, Kim MO, Zhao ML, Suh HS, Lee SC. CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. Brain Pathol. 2006;16:256-265.
59. Kokovay E, Cunningham A. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol. 2005;19:471-478.
60. Glavaski-Joksimovic A, Bohn MC. Mesenchymal stem cells and neuroregeneration in Parkinson's disease. Exp Neurol. 2013;247:25-38.
61. Hellman MA, Panet H, Barhum Y, Melamed E, Offen D. Increased survival and migration of mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett. 2006;395:124-128.
62. Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae JS. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid- beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem cell. 2010;28:329-343.
63. Speciale SG. MPTP Insights into parkinsonian neurodegeneration. Neurotoxicol Teratol. 2002;24:607-620.
64. Perry JC, Hipólide DC, Tufik S, Martins RD, Da Cunha C, Andreatini R, Vital MA. Intra-nigral MPTP lesion in rats: Behavioural and autoradiography studies. Exp Neurol. 2005;195:322-329.